GenCurix Hosts Breast Cancer Awareness Event on Women's Health Day

[Asia Economy Reporter Hyungsoo Park] GenCurix announced on the 10th that it will hold breast cancer patient support activities and breast cancer awareness improvement events in celebration of ‘Women’s Health Day’.

A company official said, "We have prepared various events related to our main service, the breast cancer prognosis test ‘Jinswell BCT’," adding, "We will strive to improve awareness of breast cancer, the number one cancer among women, and to elicit empathy and support for patients."

Every year, May 10th is designated as ‘Women’s Health Day.’ In 2007, the Korean Society of Obstetrics and Gynecology designated this day to raise social awareness about women’s health and to build healthy families and societies on the occasion of its 60th anniversary.

GenCurix will conduct events such as the ▲Jinswell Heart Delivery Bouquet Event ▲Breast Cancer Webtoon ‘Biroso Boineun Geotdeul’ Instagram Sharing Event. Since 2020, GenCurix has produced the webtoon ‘Biroso Boineun Geotdeul’ to encourage and support patients battling breast cancer and to create opportunities for social empathy toward breast cancer awareness and cancer survivors. They have collected real stories from breast cancer patients and produced a total of 45 episodes as webtoons to date. ‘Biroso Boineun Geotdeul’ faithfully depicts the life changes after experiencing cancer and the process of overcoming it, gaining much empathy and attention from many people.

They will also hold the ‘Jinswell Heart Delivery Event.’ This event conveys gratitude on behalf of GenCurix with beautiful bouquets to ‘patients’ who are enduring difficult treatment periods well and to ‘caregivers’ who steadfastly support them.

A GenCurix official said, "We hope this will be an opportunity to give courage and support to those battling breast cancer and to elicit empathy and support for cancer survivors from those who have not experienced cancer."

Jinswell BCT is a breast cancer prognosis test approved by the Ministry of Food and Drug Safety. Numerous clinical trials have proven that patients classified as low-risk through the test show high survival rates regardless of whether they undergo chemotherapy. Jinswell BCT is expanding its market share through reliability gained from official approval and price differentiation utilizing indemnity insurance.

This content was produced with the assistance of AI translation services.